Genetic alterations in differentiated thyroid cancers

Endocrine, Metabolic and Immune Disorders - Drug Targets

Volumn 9, Issue 3, 2009, Pages 257-268

  Salehian, Behrouz ^a   Liu, Zhong ^a   Kandeel, Fouad ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BORTEZOMIB; CD135 ANTIGEN; FAS ANTIGEN; FAS LIGAND; GAMMA INTERFERON; GELSOLIN; HISTONE DEACETYLASE 1; MAPATUMUMAB; METHAMPHETAMINE; MINOCYCLINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHOPROTEIN DARPP 32; PIOGLITAZONE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN PATCHED; PROTEIN RET; RAF PROTEIN; ROSIGLITAZONE; SORAFENIB; STEM CELL FACTOR; SUNITINIB; SURAMIN; TANESPIMYCIN; TRANSCRIPTION FACTOR PAX8; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VORINOSTAT; BRAF PROTEIN, HUMAN; RET PROTEIN, HUMAN; THYROID HORMONE RECEPTOR;

CANCER GENETICS; CANCER INVASION; CARCINOGENESIS; CELL PROLIFERATION; GENE MUTATION; HUMAN; METASTASIS; REVIEW; THYROID CANCER; TUMOR DIFFERENTIATION; GENETICS; MUTATION; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; THYROID TUMOR;

ANTIGENS, CD95; HUMANS; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PPAR GAMMA; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RET; RECEPTORS, THYROID HORMONE; SIGNAL TRANSDUCTION; THYROID NEOPLASMS;

EID: 70350505880     PISSN: 18715303     EISSN: None     Source Type: Journal    
DOI: 10.2174/187153009789044338     Document Type: Review

References (58)

1. Braverman, L.E. (2005) Werner and Ingbar's The Thyroid: A Fundamental and Clinical Text. Lippincott Williams & Wilkins, 8th Ed., 1144.
2. Kondo, T.; Ezzat, S. and Asa, S.L. (2006) Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat. Rev. Cancer, 6(4), 292-306.
3. Ciampi, R. and Nikiforov, E. (2007) RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology, 148(3), 936-941.
4. Mitsutake, N.; Kauf, J.A.; Mitsutake, S.; Aken, N.; Mesa Jr, C.; Zhang, L. and Fagin, J.A. (2005) The BRAF gene encodes a serine/threonine kinase that serves as an immediate downstream effector of RAS. Cancer Res., 65(6), 2465-2473.
5. Mazzaferri, E.L. and Kloos, R.T. (2001) Current approaches to primary therapy for papillary and follicular thyroid cancer. J. Clin. Endocrinol. Metab., 86(4), 1447-1463.
6. Hundahl, S.A.; Fleming, I.D.; Fremgen, A.M. and Menck, H.R. (1998) A national cancer data base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer, 83(12), 2638-2648.
7. Espinosa, A.V.; Porchia, L. and Ringel, M.D. (2007) Targeting BRAF in thyroid cancer. Br. J. Cancer, 96(1), 16-20.
8. Xing, M.; Tufano, R.P.; Tufaro, A.P.; Basaria, S.; Ewertz, M.; Rosenbaum, E.; Byrne, P.J.; Wang, J.; Sidransky, D. and Ladenson, P.W. (2004) Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J. Clin. Endocrinol. Metab., 89(6), 2867-2872.
9. Trovisco, V.; Soares, P.; Preto, A.; de Castro, I.V.; Lima, J.; Castro, P.; Maximo, V.; Botelho, T.; Moreira, S.; Meireles, A.M.; Magalhaes, J.; Abrosimov, A.; Cameselle-Teijeiro, J. and Sobrinho-Simoes, M. (2005) Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Archives, 446, 589-595.
10. Ciampi, R.; Knauf, J.A.; Kerler, R.; Gandhi, M.; Zhu, Z.; Nikiforova, M.N.; Rabes, H.M.; Fagin, J.A. and Nikiforov, Y.E. (2005) Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J. Clin. Invest., 115(1), 94-101.
11. V600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res., 65(10), 4238-4245.
12. Kimura, E.T.; Nikiforova, M.N.; Zhu, Z.; Knauf, J.A.; Nikiforov, Y.E. and Fagin, J.A. (2003) High prevalence of BRAF mutations in thyroid cancer. Cancer Res., 63(7), 1454-1457.
13. Mesa Jr, C.; Mirza, M.; Mitsutake, N.; Sartor, M.; Medvedovic, M.; Tomlinson, C.; Knauf, J.A.; Weber, G.F. and Fagin, J.A. (2006) Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling. Cancer Res., 66(13), 6521-6529.
14. Riesco-Eizaguirre, G.; Gutierrez-Martinez, P.; Garcia-cabezas, M.A.; Nistal, M. and Santisteban, P. (2006) The oncogene BRAFV600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. Endocr. Relat. Cancer, 13(1), 257-269.
15. Martelli, M.L.; Iuliano, R.; Le Pera, I.; Sama', I.; Monaco, C.; Cammarota, S.; Kroll, T.; Chiariotti, L.; Santoro, M. and Fusco, A. (2002) Inhibitory effects of peroxisome proliferator-activated receptor γ on thyroid carcinoma cell growth. J. Clin. Endocrinol. Metab., 87(10), 4728-4735.
16. Krey, G.; Braissant, O.; L'Horset, F.; Kalkhoven, E.; Perroud, M.; Parker, M.G. and Wahli, M. (1997) Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol. Endocrinol., 11(6), 779-791.
17. Ohta, K.; Endo, T.; Haraguchi, K.; Hershman, J.M. and Onaya, T. (2001) Ligands for proxisome proliferator-activated receptor γ inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J. Clin. Endocrinol. Metab., 86(5), 2170-2177.
18. Rieusset, J.; Andreelli, D.; Auboeuf, D.; Roques, M.; Vallier, P.; Riou, J.P.; Auwerx, J.; Laville, M. and Vidal, H. (1999) Insulin acutely regulates the expression of the peroxisome proliferator-activated receptorgamma in human adipocytes. Diabetes, 48(4), 699-705.
19. Lefebvre, A.M.; Laville, M.; Vega, N.; Riou, J.P.; van Gaal, L.; Auwerx, J. and Vidal, H. (1998) Depot-specific differences in adipose tissue gene expression in lean and obese subjects. Diabetes, 47(1), 98-103.
20. Chung, S.H.; Naoyoshi, O.; Tetsuro, S.; Ogisawa, K.; Takenaka, C.; Yano, Y.; Hato, F. and Hirakawa, K. (2002) Peroxisome proliferator-activated receptor gamma activation induces cell cycle arrest via the p53-independent pathway in human anaplastic thyroid cancer cells. Jpn. J. Cancer Res., 93(12), 1358-1365.
21. Demetri, G.D.; Fletcher, C.D.M.; Mueller, E.; Sarraf, P.; Naujoks, R.; Campbell, N.; Spiegelman, B.M. and Singer, S. (1999) Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc. Nat. Acad. Sci. USA, 96(7), 3951-3956.
22. Kubota, T.; Koshizuka, K.; Williamson, E.A.; Asou, H.; Said, J.W.; Holden, S.; Miyoshi, I. and Koeffler, H.P. (1998) Ligand for peroxisome proliferator-activated receptor γ (Troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res., 58(15), 3344-3352.
23. Ohta, K.; Endo, T.; Haraguchi, K.; Hershman, J.M. and Onaya, T. (2001) Ligands for peroxisome proliferator-activated receptor γinhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J. Clin. Endocrinol. Metab., 86(5), 2170-2177.
24. Zannini, M.; Francis-Lang, H.; Plachov, D. and Di Lauro, R. (1992) Pax-8, a paired domain-containing protein, binds to a sequence overlapping the recognition site of a homeodomain and activates transcription from two thyroid-specific promoters. Mol. Cell. Biol., 12(9), 4230-4241.
25. Francis-Lang, H.; Price, M.; Polycarpou-Schwarz, M. and Di Lauro, R. (1992) Mol. Cell-type-specific expression of the rat thyroperoxidase promoter indicates common mechanisms for thyroid-specific gene expression. Mol. Cell Biol., 12(2), 576-588.
26. Artelli, M.L.; Iuliano, R.; Le Pera, I.; Sama', I.; Monaco, C.; Cammarota, S.; Kroll, T.; Chiariotti, L.; Santoro, M. and Fusco, A. (2002) Inhibitory effects of peroxisome proliferator-activated receptor γ on thyroid carcinoma cell growth. J. Clin. Endocrinol. Metab., 87(10), 4728-4735.
27. Rossi, D.L.; Acebron, A. and Santisteban, P. (1995) Function of the homeo and paired domain proteins TTF-1 and Pax-8 in thyroid cell proliferation. BJC on line (www.JBC.org/cgi/content /full/270/39/23139), 270(39), 23139-23142.
28. Takahashi, M. (1988) Structure and expression of the RET transforming gene. IARC Sci. Publ., 1988(92), 189-197.
29. Santoro, M.; Dathan, N.A.; Berlingieri, M.T.; Bongarzone, I.; Paulin, C.; Grieco, M.; Pierotti, M.A.; Vecchio, G. and Fusco, A. (1994) Molecular characterization of RET/PTC3; a novel rearranged version of the RET proto-oncogene in a human thyroid papillary carcinoma. Oncogene, 9(2), 509-516.
30. Fusco, A.; Grieco, M.; Santoro, M.; Berlingieri, T.; Pilotti, S.; Pierotti, M.A.; Della Porta, G. and Vecchio, G. (1987) A new oncogene in human thyroid papillary carcinomas and their lymphnodal metastases. Nature, 328(1987), 170-172.
31. Grieco, M.; Santoro, M.; Berlingieri, M.T.; Melillo, R.M.; Donghi, R.; Bongarzone, I.; Pierotti, M.A.; Della Porta, G.; Fusco, A. and Vecchio, G. (1990) PTC is a novel rearranged form of the ret proto-oncogene and is frequently in vivo in human thyroid papillary carcinomas. Cell, 60(4), 557-563.
32. Jhiang, S.M.; Sagartz, J.E.; Tong, Q.; Parker-Thornburg, J.; Capen, C.C.; Cho, J.Y.; Xing, S. and Ledent, C. (1996) Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. Endocrinology, 137(1), 375-378.
33. Knauf, J.A.; Ouyang, B.; Croyle, M.; Kimura, E. and Fagin, J.A. (2003) Acute expression of RET/PTC induces isozyme-specific activation and subsequent downregulation of PKCepsilon in PCCL3 thyroid cells. Oncogene, 22(44), 6830-6838.
34. Fuggazzola, L.; Pillotti, S.; Pinchera, A.; Vorontsova, T.V.; Mondellini, P.; Bongarzone, I.; Greco, A.; Astakhova, L.; Butti, M.G.; Demidchik, E.P.; Pacini, F. and Pierotti, M.A. (1995) Oncogenic rearrangements of the RET proto-oncogene in papillary thyroid carcinomas from children exposed to the chernobyl nuclear accident. Cancer Res., 55(23), 5617-5620.
35. Ciampi, R. and Nikiforov, Y.E. (2007) RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology, 148(3), 3936-3941.
36. Pines, A.; Bivi, N.; Vascotto, C.; Romanello, M.; D'Ambrosio, C.; Scaloni, A.; Damante, G.; Morisi, R.; Filetti, S.; Ferretti, E.; Quadrifoglio, F. and Tell, G. (2006) Nucleotide receptors stimulation by extracellular ATP controls Hsp90 expression through APE1/Ref-1 in thyroid cancer cells: a novel tumorigenic pathway. J. Cell Physiol., 209(1), 44-55.
37. Trapasso, F.; Iuliano, R.; Chiefari, E.; Arturi, F.; Stella, A.; Filetti, S.; Fusco, A. and Russo, D. (1999) Iodide symporter gene expression in normal and transformed rat thyroid cells. Eur. J. Endocrinol., 140(5), 447-451.
38. Knauf, J.A.; Kuroda, H.; Basu, S. and Fagin, J.A. (2003) RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase. Oncogene, 22(28), 4406-4412.
39. Pines, A.; Bivi, N.; Vascotto, C.; Romanello, M.; D'Ambrosio, C.; Scaloni, A.; Damante, G.; Morisi, R.; Filetti, S.; Ferretti, E.; Quadrifoglio, F. and Tell, G. (2006) Nucleotide receptors stimulation by extracellular ATP controls Hsp90 expression through APE1/Ref-1 in thyroid cancer cells: A novel tumorigenic pathway. J. Cell Physiol., 209(1), 44-55.
40. Miyagi, E.; Braga-Basaria, M.; Hardy, E.; Vasko, V.; Burman, K.D.; Jhiang, S.; Saji, M. and Ringel, M.D. (2004) Chronic expression of RET/PTC 3 enhances basal and insulin-stimulated PI3 kinase/AKT signaling and increases IRS-2 expression in FRTL-5 thyroid cells. Mol. Carcinog., 41(2), 98-107.
41. Mitsiades, C.S.; Poulaki, V.; Fanourakis, G.; Sozopoulos, E.; McMillin, D.; Wen, Z.; Voutsinas, G.; Tseleni-Balafouta, S. and Mitsiades, N. (2006) Fas signaling in thyroid carcinomas is diverted from apoptosis to proliferation. Clin. Cancer Res. 12(12), 3705-3712.
42. Mitsiades, C.S.; Poulaki, V. and Mitsiades, N. (2003) The role of apoptosis-inducing receptors of the tumor necrosis factor family in thyroid cancer. J. Endocrinol., 178(2), 205-216.
43. Muzio, M.; Stockwell, B.R.; Stennicke, H.R.; Salvesen, G.S. and Dixit, V.M. (1998) An induced proximity model for caspase-8 activation. J. Biol. Chem., 273(5), 2926-2930.
44. Salveson, G.S. and Dixit, V.M. (1999) Caspase activation: the induced-proximity model. Proc. Natl. Acad. Sci. USA, 96(20), 10964-10967.
45. Tolcher, A.W.; Mita, M.; Meropol, N.J.; von Mehren, M.; Patnaik, A.; Padavic, K.; Hill, M.; Mays, T.; McCoy, T.; Fox, N.L.; Halpern, W.; Corey, A. and Cohen, R.B. (2007) Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J. Clin. Oncol., 25(11), 1390-1395.
46. Damante, G.; Tell, G. and Di Lauro, R. (2001) A unique combination of transcription factors controls differentiation of thyroid cells. Prog. Nucleic. Acid Res. Mol. Boil., 66, 307-356.
47. García-Jiménez, C.; Zaballos, M.A. and Santisteban, P. (2005) DARPP-32 (dopamine and 3',5'-cyclic adenosine monophosphate-regulated neuronal phosphoprotein) is essential for the maintenance of thyroid differentiation. Mol. Endocrinol., 19(12), 3060-3072.
48. Bassett, J.H.; Harvey, C.B. and Williams, G.R. (2003) Mechanisms of thyroid hormone receptor-specific nuclear and extra nuclear actions. Mol. Cell Endocrinol., 213(1), 1-11.
49. Yen, P.M.; Andob, S.; Feng, X.; Liu, Y.; Maruvadab, P. and Xia, X. (2006) Thyroid hormone action at the cellular, genomic and target gene levels. Mol. Cell Endocrinol., 246(1-2), 121-127.
50. Rosenfeld, M.G.; Lunyak, V.V. and Glass, C.K. (2006) Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev., 20(11), 1405-1428.
51. Tsai, C.C. and Fondell, J.D. (2004) Nuclear receptor recruitment of histone-modifying enzymes to target gene promoters. Vitam. Horm., 68, 93-122.
52. Suzuki, H.; Willingham, M.C. and Cheng, S.Y. (2002) Mice with a mutation in the thyroid hormone receptor beta gene spontaneously develop thyroid carcinoma: a mouse model of thyroid carcinogenesis. Thyroid, 12(11), 963-969.
53. Ringel, M.D.; Hayre, N.; Saito, J.; Saunier, B.; Schuppert, F.; Burch, H.; Bernet, V.; Burman, K.D.; Kohn, L.D. and Saji, M. (2001) Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res., 61(16), 6105-6111.
54. Kim, D.; Pemberton, H.; Stratford, A.L.; Buelaert, K.; Watkinson, J.C.; Lopes, V.; Franklyn, J.A. and McCabe, C.J. (2205) Pituitary tumour transforming gene (PTTG) induces genetic instability in thyroid cells. Oncogene, 24(30), 4861-4866.
55. Zimonjic, D.B.; Kato, Y.; Ying, H.; Popescu, N.C. and Cheng, S.Y. (2005) Chromosomal aberrations in cell lines derived from thyroid tumors spontaneously developed in TRbetaPV/PV mice. Cancer Genet. Cytogenet., 161(2), 104-109.
56. Yeh, M.W.; Rougier, J.P.; Park, J.W.; Duh, Q.Y.; Wong, M.; Werb, Z. and Clark, O.H. (2006) Differentiated thyroid cancer cell invasion is regulated through epidermal growth factor receptor-dependent activation of matrix metalloproteinase (MMP)-2/gelatinase A. Endocr. Relat. Cancer, 13(4), 1173-1183.
57. Dace, A.; Zhao, L.; Park, K.S.; Furuno, T.; Takamura, N.; Nakanishi, M.; West, B.L.; Hanover, J.A. and Cheng, S.Y. (2000) Hormone binding induces rapid proteasome-mediated degradation of thyroid hormone receptors. Proc. Natl. Acad. Sci. USA, 97(16), 8985-8990.
58. Sancho, M.; Vieira, J.M.; Casalou, C.; Mesquita, M.; Pereira, T.; Cavaco, B.M.; Dias, S. and Leite, V. (2006) Expression and function of the chemokine receptor CCR7 in thyroid carcinomas. J. Endocrinol., 191(1), 229-238.